{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'Subject noncompliance with study drug or to the protocol.', 'The subject has a QTcF > 500 msec (confirmed on repeat ECG testing).', 'The subject has a QTcF increase of more than 60 msec (confirmed by repeat ECG)', 'from the mean QTcF value obtained from triplicate ECGs obtained at the baseline', 'visit and a simultaneous absolute QTcF > 450 msec (male) or 470 msec (female).', 'Subjects with a study drug-related Grade 3 or 4 rash as described by the Division of', 'Microbiology and Infectious Diseases (DMID) criteria \"skin-mucocutaneous\" will be', 'discontinued from study drug and treated according to best medical practice.', 'All subjects with a suspected drug rash should undergo specific rash evaluation as', 'described in Section 12.2.1. A Grade 3 rash is defined as vesiculation or moist', 'desquamation or ulceration and a Grade 4 rash is defined as exfoliative dermatitis,', 'mucous membrane involvement or erythema multiforme or suspected', 'Stevens-Johnson syndrome or necrosis requiring surgery. Subjects with a Grade 1 or', '2 study drug-related rash may be continued on BCX7353 if the investigator, subject,', 'and sponsor deem it appropriate. The protocol for continuing BCX7353 in the', 'presence of a rash is described in Section 12.2.1.', 'Subjects who discontinue from study drug in Parts 1 or 2 will be requested to complete all', 'regularly scheduled visits and procedures outlined in Table 2 and Table 3 through the end of the', 'study part (ie, Part 1 or 2) in which they were currently being treated. Subjects who discontinue', 'in Part 1 will be requested to complete all regularly scheduled visits and procedures through', 'Week 24. Subjects who discontinue in Part 2 will be requested to complete all regularly', 'scheduled visits and procedures through Week 52. Subjects who discontinue in Part 3 will have', 'an EOS visit 3 weeks after the last dose of study drug. All subjects who discontinue from all', 'parts should be treated in accordance with local clinical practice for HAE.', 'If a subject who discontinues from study drug subsequently withdraws consent to continue study', 'visits as previously outlined, please see Section 8.3.1.', 'Subjects are not eligible for treatment in Parts 2 or 3 if they discontinue study drug in', 'Parts 1 or 2, respectively due to any of the above cited reasons.', '8.4.', 'End of Study Definition', 'The end of study will be defined as when the last subject completes the last protocol-scheduled', 'study visit.', 'Once BCX7353 receives marketing authorization in Japan, this study will be transitioned to a', 'post-marketing study. Each subject remaining on study may continue to receive access to', 'BCX7353 until such time as BCX7353 is commercially available at his or her site, unless the', 'subject discontinues his or her participation in the study. Once the last subject is able to access', 'commercial drug product or discontinues from the study, the study will be terminated.', '47']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', '9.', 'TREATMENT OF SUBJECTS', '9.1.', 'Description of Study Drug and Study Drug Product', 'BCX7353 is an oral, small molecule inhibitor of plasma kallikrein. All subjects will receive a', 'dose of BCX7353 (150 or 110 mg) or matching placebo (Part 1 only) capsules for oral', 'administration once daily for up to 104 weeks (placebo capsules will be administered for', '24 weeks followed by once daily treatment with BCX7353 for up to 80 weeks). Study drug or', 'investigational medicinal product (IMP) in this study consists of BCX7353 and placebo capsules.', 'The investigational active pharmaceutical ingredient (API) is BCX7353, which is supplied as', '55 or 75 mg capsules in Parts 1 and 2 and as a 150 mg capsule in Part 3. The capsules are', 'composed of the API (BCX7353) blended with the excipients pregelatinized starch,', 'polyplasdone XL, colloidal silicon dioxide, and magnesium stearate in a gelatin capsule.', 'The matching placebo will also be provided as capsules to match the BCX7353 capsules.', 'The matching placebo will contain microcrystalline cellulose and magnesium stearate.', 'In Parts 1 and 2, subjects will be instructed to take 2 capsules of study drug (55 or 75 mg', 'capsules) together at the same time daily. In Part 3, subjects will take a single capsule of', 'study drug (150 mg capsule) daily. After the study has been transitioned to a post-marketing', 'study following marketing authorization of BCX7353, BCX7353 will be administered at the', 'dose regimen that is approved in Japan.', 'Additional details for the chemical and physical characteristics of BCX7353 may be found in', 'the IB.', '9.2.', 'Description of Study Drug Packaging, Labeling, and Storage', 'The study drug will be packaged in bottles. Subjects will be dispensed a sufficient number of', 'bottles and capsules to cover the dosing period until the next study visit.', 'Each bottle of study drug will be labeled with the information required per local law and may', 'include the following: sponsor name, study protocol number, description of the contents, expiry', 'date, kit number, and either a statement regarding the investigational (clinical trial) or', 'post-marketing clinical study use of the study drug, as applicable.', 'Study drug must be stored between 15\u00b0C and 25\u00b0C (room temperature).', 'Details on the study drug packaging, labeling, shipment, storage, and dispensing will be provided', 'in the IMP manual.', '9.3.', 'Randomization and Study Drug Blinding', '9.3.1.', 'Blinding', 'This is a double-blind study throughout both Parts 1 and 2. As such, study drug assignment will', 'be blinded to the investigator, study staff, study subjects, and clinical research organization staff.', 'Part 3 will be open-label. No blinding will be used.', 'During Part 1, sponsor employee(s) will also be blinded to the treatment allocation of individual', 'subjects, with the exception of sponsor staff responsible for managing clinical supplies.', '48']\n\n###\n\n", "completion": "END"}